Contributions by the Commission to the work of the Economic and Social Council, in line with General Assembly resolution 72/305, including follow-up to and review and implementation of the 2030 Agenda for Sustainable Development.
Draft resolution submitted by the Chair on behalf of the Commission on Narcotic Drugs.
Follow-up to the implementation at the national, regional and international levels of all commitments, as reflected in the Ministerial Declaration of 2019, to address and counter the world drug problem.
От имени делегации Кыргызской Республики позвольте поприветствовать всех участников 64-й сессии Комиссии по наркотическим средствам, а также поздравить Вас, госпожа Кроис с избранием на высокий пост!
Мы поддерживаем предложенную повестку дня сессии и приветствуем избрание представителя Кыргызской Республики на должность Докладчика.
[...] conventions were adopted by the international community to address global health challenges through global coordination and rules. In that regard, I welcome the adoption today of a joint statement on the impact of the COVID-19 pandemic, which urges Member States to ensure that no one affected by the world drug problem is left behind.
This is in keeping with the spirit of both Conventions, which aim to protect the health and well-being of humankind by ensuring the availability （买得着）and accessibility （用得上）of drugs for medical and scientific purposes, while preventing their misuse.
UNODC-WHO Informal Scientific Network Statement 2021: Recommendations on Prevention, Treatment, and Care of Substance Use Disorders in Times of COVID-19.
Individuals with substance use disorders are at increased risk of contracting COVID-19 and if infected are more likely to experience negative outcomes. This vulnerability reflects both the adverse effects of the non-medical use of psychoactive substances on health, as well as associated psychosocial and structural factors, including poverty and stigma. Therefore, individuals with substance use disorders should be prioritized for COVID-19 screening and vaccination. Resources necessary to prevent infection, provide correct information, and ensure treatment, should be made available to this population. Governments need to build capacities to collect timely data on substance use and substance use disorders during the COVID-19 pandemic. Evidence-based treatment of substance use disorders, including mental health and physical comorbidities, should be considered essential, and integrated into existing health care services.
Consisting of five separate booklets, the World Drug Report 2021 provides an in-depth analysis of the global drug markets and paints a comprehensive picture of the measurable effects and potential impact of the COVID-19 crisis on the world drug problem.
The World Drug Report 2021 is aimed not only at fostering greater international cooperation to counter the impact of the world drug problem on health, governance and security, but also, with its special focus on the impact of the COVID-19 pandemic, at assisting Member States in anticipating and addressing challenges that may arise in the near future. See World Drug Report website for additional details.
The present report contains an overview of the activities conducted by the United Nations Office on Drugs and Crime in 2019. It also contains a set of recommendations for consideration by the Commission on Narcotic Drugs and the Commission on Crime Prevention and Criminal Justice. The report also contains information submitted pursuant to the requests set out in resolutions 56/9, 62/3, 62/7 of the Commission on Narcotic Drugs and resolution 2019/23 of the Economic and Social Counci.
The Commission on Narcotic Drugs and the Commission on Crime Prevention and Criminal Justice have before them, for their information, an advance unedited version of the draft proposed programme plan for 2021 and performance information for 2019 on international drug control, crime and terrorism prevention and criminal justice.
The International Drug Policy Consortium (IDPC) is a global network of 192 NGOs that focus on issues related to drug production, trafficking and use. IDPC promotes objective and open debate on the effectiveness, direction and content of drug policies at the national and international level, and supports evidence-based policies that are effective at reducing drug-related harm. Our advocacy positions are based on five core policy principles. We produce briefing papers, disseminate key resources on drug policy, build the advocacy capacity of our members and partners, and offer expert advice to policy makers and officials around the world. Our global membership has expertise and experience on the wide spectrum of drug policy issues.
Presented in six separate booklets, the World Drug Report 2020 provides a wealth of information and analysis to support the international community in implementing operational recommendations on a number of commitments made by Member States, including the recommendations contained in the outcome document of the special session of the General Assembly on the world drug problem, held in 2016.
This, the second booklet of the World Drug Report 2020, contributes evidence to support the international community in implementing operational recommendations on drug demand reduction and treatment, as well as other health-related outcomes, including those contained in the outcome document of the special session of the General Assembly on the world drug problem, held in 2016.
The booklet provides a global overview of the extent of and trends in drug use, including drug use disorders, and its health consequences. Using the latest estimates as a basis, the booklet reviews the general situation and trends in the use of each drug type in the main consumer markets at the subregional level. It then addresses the health impact of drug use, including the global number of deaths and years of “healthy” life lost as a result of drug use. The booklet concludes with an analysis of the number of people who inject drugs and those among them who are living with HIV and hepatitis.
This, the third booklet of the World Drug Report 2020, contributes evidence to support the international community in implementing operational recommendations dedicated to supply reduction and related measures, effective law enforcement and responses to drug-related crime, including the recommendations contained in the outcome document of the special session of the General Assembly, held in 2016.
The booklet provides an overview of the extent of illicit crop cultivation and trends in drug trafficking at the global and regional levels. The analysis is presented by drug type and, using the latest estimates as a basis, the booklet reviews the general situation and trends in the supply of opiates, cocaine, amphetamine-type stimulants and cannabis. In addition, some issues emerging in these markets are discussed, such as the impact of changes in illicit crop cultivation and production along the drug supply chain to the main consumption markets, and emerging markets along the drug trafficking routes and beyond in other regions.
This, the fourth booklet of the World Drug Report 2020, contributes evidence to support the international community in implementing operational recommendations on cross-cutting issues for addressing and countering the world drug problem, in particular its evolving reality, trends and existing circumstances, as well as emerging and persistent challenges and threats, including the recommendations contained in the outcome document of the special session of the General Assembly, held in 2016.
The booklet first analyses the macro-dynamics that are driving the expansion and increasing complexity of the drug markets. Factors such as population growth, urbanization and income levels and distribution are examined, the interplay between a number of substances at the manufacture, trafficking and use levels is considered, and the question on whether changes in drug markets are mostly demand-, supply- or control-driven is addressed.
This, the fifth booklet of the World Drug Report 2020, contributes evidence to support the international community in implementing operational recommendations on cross-cutting issues in relation to drugs and human rights, youth, children, women and communities, including the recommendations contained in the outcome document of the special session of the General Assembly on the world drug problem held in 2016. Many of these cross-cutting issues are complex and their analysis would require the mobilization of evidence that is not always readily available. For this reason, this booklet focuses on one issue in particular: the association between socioeconomic characteristics and drug use disorders.
The booklet begins with a discussion of general concepts of population health in order to shed light on ways in which socioeconomic characteristics are associated with drug use disorders. Next it reviews evidence regarding the association between socioeconomic characteristics and drug use disorders, from those characteristics at the macro and population levels to those at the community level that may define more vulnerable neighbourhoods. The influence of individual-level circumstances and indicators of socioeconomic position on drug use and drug use disorders are then addressed.
This, the sixth booklet of the World Drug Report 2020, addresses a number of drug policy issues that all form part of the international debate on the drug problem and how to address it. Although comprehensive data and analysis may not be available for some of these issues, the following chapters represent a first attempt to consolidate available evidence aimed at supporting the international community in implementing several operational recommendations, including those contained in the outcome document of the special session of the General Assembly, held in 2016.
The booklet starts by considering the issue of ensuring the availability of and access to controlled substances exclusively for medical and scientific purposes while preventing their diversion. It thus reviews the latest data on and trends in the availability of controlled medicines, specifically opioids, for medical consumption at the global level and across regions. An overview is also provided of the latest survey findings on barriers to access to controlled medicines for medical purposes in Member States.
The EU Drugs Strategy 2021-2025 (hereinafter referred to as ‘the Strategy’) provides the overarching political framework and priorities for the European Union’s drugs policy for the period 2021-2025. The framework, aim and objectives of this Strategy will serve as the basis for the EU Action Plan on Drugs from 2021 to 2025.
Цель закона – совершенствование и унификация действующего антинаркотического законодательства, установление правовых основ и механизма для обеспечения эффективного государственного контроля над оборотом новых видов психоактивных веществ
Sustainable, rights-based action on drug control requires shared standards from which to begin. Yet there remains a lack of clarity as to what human rights law requires of States in the context of drug control law, policy, and practice. The International Guidelines on Human Rights and Drug Policy are the result of a three-year consultative process to address this gap.
The Guidelines highlight the measures States should undertake or refrain from undertaking in order to comply with their human rights obligations, while taking into account their concurrent obligations under the international drug control conventions: the 1961 Single Convention on Narcotic Drugs (as amended); the 1971 Convention on Psychotropic Substances; and the 1988 United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances.3 Critically, they do not invent new rights. They apply existing human rights law to the legal and policy context of drug control in order to maximise human rights protections, including in the interpretation and implementation of the drug control conventions.
The Guidelines are not a ‘toolkit’ for a model drug policy. Rather, they respect the diversity of States and their legitimate prerogative to determine their national policies in line with applicable human rights law. States always retain the freedom to apply more favourable human rights protections than those provided for under international law. The Guidelines are therefore a reference tool for those working to ensure human rights compliance at local, national, and international levels, be they parliamentarians, diplomats, judges, policy makers, civil society organisations, or affected communities.
Безмедикаментозное лечение в Германии. Повышенный риск при употреблении наркотиков и нъективным путем. Повышенный риск при употреблении наркотиков и нъективным путем.
Прекращение эпидемии СПИДа к 2030 году - одна из задач в списке целей устойчивого развития (ЦУР), которая была единогласно принята странами-членами ООН. Полученный опыт в решении проблем ВИЧ-инфекции будет играть определяющую роль в успешном достижении многих ЦУР, в частности, ЦУР 3 («Хорошее здоровье и благополучие»), а также целей касательно вопросов гендерного равенства и расширения прав и возможностей женщин, устранения неравенства между полами, глобального сотрудничества, а также установления принципов справедливости, мира и равноправия в обществе.
Представители от Республики Казахстан приняли активное участие в Совещании высокого уровня Генеральной Ассамблеи ООН по вопросам борьбы со СПИД, которое прошло в Нью-Йорке 8-10 июня 2016 года. Благодаря консолидированной позиции международного сообщества, на совещании высокого уровня, была одобрена Политическая декларация по ВИЧ/СПИДу: ускоренными темпами к активизации борьбы с ВИЧ и прекращению эпидемии СПИДа к 2030 году. Декларация была принята всеми странами-членами ООН, включая Республику Казахстан.
Для достижения целей политической декларации, Объединенная Программа ООН по ВИЧ/СПИД (ЮНЭЙДС) разработала глобальную стратегию «Ускорение: прекращение эпидемии СПИДа к 2030 году», включая достижение целей 909090 к 2020 году.
Outcome document of the thirtieth special session of the General Assembly, entitled “Our joint commitment to effectively addressing and countering the world drug problem”
Prisons play an important role in drug policy. They are used to punish people who break drug laws and they also hold a large number of people who have experience of drug use and drug problems. They therefore have an important part to play in attempts to reduce the harm caused by drugs. Imprisonment itself can be seen as one type of harm, as it causes problems for prisoners and their families and creates a large fi nancial burden for taxpayers. These harms and costs are diffi cult to calculate, but there is little evidence that large scale imprisonment of drug offenders has had the desired results in deterring drug use or reducing drug problems (Bewley- Taylor, Trace, & Stevens, 2005).
In this paper, we examine the international prevalence of drug users, drug use and related problems in prisons and we report on the problems that are related to the issue of drugs in prison. We go on to examine the international guidelines and effective responses that have been developed in this area in the last decade. The paper is a review of the literature, based on a search of bibliographic databases including Medline, PubMed, ISI as well as EMBASE and contacts with researchers and practitioners in the fi eld up to January 2007.
We hope that this paper provides an accessible guide to policymakers and service designers who are considering the appropriate responses, or evaluating and refi ning existing responses, to drug use in prisons in their own country.